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INTRODUCTION
Serotonin antagonists have been extensively studied
over the last 15 years in terms of efficacy to prevent and
control nausea and vomiting due to emetogenic chemo-
therapy and pharmacology. Numerous comparative trials
have found intravenous (IV) granisetron (Kytril; SmithKline
Beecham, Philadelphia, PA) and ondansetron (Zofran; Glax-
oWellcome, Research Triangle Park, NC) to be equally efﬁ-
cacious in the prevention of nausea and vomiting secondary
to highly emetogenic chemotherapy [1-7]. Recently, 2 sepa-
rate trials established oral granisetron and oral ondansetron to
be equivalent to IV ondansetron in the prevention of cisplatin-
induced emesis [8,9].
To date, there are no published comparative trials using
5-HT3 antagonists deﬁning optimal route and schedule in
bone marrow transplantation (BMT) patients. Two BMT
trials have compared continuous infusion IV ondansetron to
IV granisetron (continuous and bolus, respectively), both
showing no signiﬁcant difference [10,11]. A trial by Frakes
et al. has determined that oral granisetron is efﬁcacious in
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ABSTRACT
The optimal management of transplantation preparative regimen–induced nausea and vomiting remains unknown. We
conducted a Phase III double-blind study to determine the efficacy and costs of oral ondansetron versus oral
granisetron versus IV ondansetron and PRN rescue antiemetics for the prevention/control of nausea and vomiting
associated with high-dose chemotherapy or chemoradiotherapy prior to stem cell transplantation. One hundred two
patients were randomized to receive either 8 mg PO ondansetron every 8 hours, 1 mg PO granisetron every 12 hours,
or 32 mg IV ondansetron every 24 hours plus 10 mg IV dexamethasone daily during and 1 day after the various
preparative regimens. Study arms were compared in terms of emetic episodes, subjective nausea, amount and cost of
rescue antiemetics used, and total costs. Response was defined as complete response (CR), no emesis with no or mild
nausea and no rescue antiemetics; major response (MR), 1 episode of emesis or moderate nausea with or without res-
cue antiemetics; and major efficacy (ME), CR + MR. Subjective nausea was assessed using a 100-mm visual analog
scale (VAS) with 0 = no nausea. Ninety-six patients completed the study; the trial was analyzed according to intention-
to-treat. Overall CR rates were: 48% for oral ondansetron, 47% for oral granisetron, and 49% for IV ondansetron.
Overall ME rates were 82% for oral ondansetron, 84% for oral granisetron, and 81% for IV ondansetron. Mean VAS
scores were 32 for oral ondansetron, 32 for oral granisetron, and 27 for IV ondansetron. None of the differences were
statistically significant. A cost analysis revealed significant differences among all arms (P = .0001, all comparisons). All
3 regimens had similar efficacy in this BMT population; oral ondansetron was the most cost-effective.
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the prevention of nausea and emesis due to high-dose
chemotherapy [12]. Oral ondansetron has proven efﬁcacy in
the prevention of total body irradiation (TBI)-induced nau-
sea and emesis [13], but it has never been studied with high-
dose chemotherapy. No study has been done in the BMT
setting comparing oral to IV 5-HT3 antagonists.
Pharmacological studies have suggested that the gastroin-
testinal (GI) tract is the primary site of action for the 5-
HT3 antagonists [14]. Peripheral serotonin release from
enterochromafﬁn cells located in the GI tract is thought to
be the initiating event ultimately resulting in emesis follow-
ing radiation and most chemotherapeutic agents [15-18].
Studies have shown, however, that there are quantitative and
qualitative differences in serotonin release depending on the
dose and the particular antineoplastic agent employed. Cis-
platin, dacarbazine, and nitrogen mustard induce a steep rise
in serotonin, peaking approximately 6 hours after chemo-
therapy [15-17]. Carboplatin causes a more modest release of
serotonin sustained beyond 24 hours [19]. In contrast, mod-
erate (500 mg/m2) doses of cyclophosphamide have not been
found to release serotonin from the GI tract, leading some
investigators to speculate that cyclophosphamide may induce
serotonin release centrally or possibly from enteric serotonin
neurons [17]. Most bone marrow conditioning regimens
contain cyclophosphamide and/or carboplatin. Considering
the intrinsic differences in the antineoplastic agents
employed as well as the higher doses used in conditioning
regimens, cisplatin-based studies may not be completely
applicable to BMT patients. The fact that oral ondansetron
and oral granisetron are only 60% bioavailable may be irrele-
vant when the GI tract is the site of action, but it may be
extremely relevant if the central nervous system plays a
greater role in cyclophosphamide-induced emesis [20,21].
BMTs are costly, and oral 5-HT3 antagonists may help to
defray part of the cost. Although costs of oral 5-HT3 antago-
nists vary depending on country and individual institutional
contracts, the average wholesale price (AWP) of 24 mg
ondansetron (8 mg three times a day) is less than the AWP of
2 mg granisetron (1 mg twice a day [BID]) in the United
States. This study was designed to compare the efﬁcacy of
oral ondansetron, oral granisetron, and IV bolus ondansetron
in the prevention/control of nausea and vomiting associated
with highly emetogenic preparative regimens prior to BMT.
In addition, we compared the relative costs of each antiemetic
regimen, including the costs of rescue antiemetics.
PATIENTS AND METHODS
This study was a single-center, comparative, randomized,
double-blind trial comparing 2 orally administered 5-HT3
antagonists, ondansetron and granisetron, to high-dose IV
bolus ondansetron in the BMT population. Patients were
stratiﬁed by sex [22] and TBI-containing versus non–TBI-
containing preparative regimens. Patients were assigned to an
inpatient or outpatient setting primarily based on the condi-
tioning regimen they were to receive. All continuous infusion
chemotherapy (STAMP V [cyclophosphamide, thiotepa, car-
boplatin] and TANC [paclitaxel, mitoxantrone, carboplatin])
was given inpatient. TBI, oral busulfan, and short IV infusion
chemotherapy were given outpatient when the presence of a
caregiver and insurance permitted. Patients were randomized
to 1 of 3 treatments: 32 mg IV bolus ondansetron as a single
daily dose, 8 mg oral (PO) ondansetron every 8 hours, or 1 mg
PO granisetron every 12 hours on each day of the preparative
regimen plus 1 additional day. In addition, all patients
received 10 mg IV dexamethasone once daily while receiving
a 5HT3 antagonist. The randomization scheme was deter-
mined by the study’s biostatistician based on a permuted
block design (K = 6). The treatment allocation scheme was
maintained by the study pharmacist, who assumed responsi-
bility for blinded drug distribution.
Patients randomized to the IV ondansetron arm received
32 mg of ondansetron with 10 mg dexamethasone in 50 cc
dextrose 5% in water (D5W) (total volume) intravenous pig-
gyback (IVPB) over 15 minutes daily at 0800 plus an extem-
poraneously prepared opaque gelatin capsules containing
lactose daily at 0800, 1600, 2000, and 2400 hours. Patients
randomized to oral ondansetron received 10 mg dexametha-
sone in 50 cc D5W (total volume) IVPB over 15 minutes at
0800 hours. Ondansetron tablets were halved and placed in
opaque gelatin capsules, with lactose filling the remaining
space. Patients received ondansetron capsules at 0800, 1600,
and 2400, plus a lactose-containing placebo capsule at
2000 hours. Patients randomized to oral granisetron received
10 mg dexamethasone in 50 cc D5W (total volume) IVPB
over 15 minutes daily at 0800 hours. Granisetron tablets
were halved and placed in opaque gelatin capsules, with lac-
tose ﬁlling the remaining space. Patients received granisetron-
containing capsules at 0800 and 2000, plus lactose-containing
capsules at 1600 and 2400 hours. For all arms, patients
received their first antiemetic 30 minutes prior to chemo-
therapy. Day 1 antiemetics were allowed to start as late as
1200, but the next dose remained timed at 1600 hours. Ben-
zodiazepines were allowed as needed for sleep. The primary
rescue antiemetic was lorazepam administered at a dose of
1 to 2 mg PO/IV every 4 hours as needed (PRN). Additional
antiemetics consisting of diphenhydramine and pro-
chlorperazine were allowed if patients had repeated episodes
of vomiting (deﬁned as >4 episodes in any 12-hour period).
Eligible patients were over 17 years of age, had malig-
nant disease, had consumed <5 alcoholic drinks per day in
the past year, and were scheduled to receive chemotherapy
or chemoradiotherapy preparative regimens. Patients were
required to have an estimated creatinine clearance of at least
50 mL/min and normal liver function, defined as a total
bilirubin <1.5 × ULN (upper limit of normal) and aspartate
aminotransferase (AST) <2 × ULN. The patient population
included both inpatient and outpatients. The protocol was
approved by the institutional review board, and a written
informed consent was obtained from each patient.
Preparative Regimens
Preparative regimens included STAMP V [23]; TBI/
etoposide (VP)/ cyclophosphamide (CY) [24]; TANC (pacli-
taxel 700 mg/m2 IV over 24 hours on day –9; mitoxantrone
30 mg/m2 IV bolus on days –8, –6, and –4; and carboplatin
[total area under the curve (AUC) = 28] continuous IV over
5 days on days –8, –7, –6, –5, and –4); busulfan (BU)/CY [25];
BEAM (carmustine, etoposide, cytosine arabinoside, and mel-
phalan) [26]; carmustine (BCNU)/VP/CY [27]; ICE (ifos-
famide, carboplatin, VP-16) [28] (carboplatin dose modiﬁed to
total AUC = 28 [29]); carboplatin/VP [30] (carboplatin dose
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modiﬁed to a total AUC = 30 [29]); carboplatine/mitoxantrone
(MTZ)/CY [31]; MMT (paclitaxel 150 mg/m2 per day contin-
uous IV infusion [CIV] over 96 hours on days –6, –5, –4, and
–3; mitoxantrone 30 mg/m2 IV over 15 minutes on days –6,
–5, and –4; and melphalan 90 mg/m2 IV over 20 minutes on
days –6 and –5); thiotepa/CY [32]; and TBI/CY [33] (Table 1).
Evaluation of Nausea and Vomiting
At the end of each treatment day, patients recorded the
severity of nausea each day by marking a visual analog scale
(VAS) indicating the degree of nausea they experienced that
day. The VAS was a 100-mm line marked “no nausea” at
one end and “severe nausea” at the other end.
For inpatients, staff nurses recorded episodes of vomiting
as well as any rescue antiemetics used on the standard BMT
critical care flow sheet. Outpatients presented daily to the
high-dose center. While the patients were in the high-dose
center, episodes of vomiting and rescue antiemetics used
were recorded by the clinic nurses. Each evening, patients
went home with a form to record episodes of vomiting and
rescue antiemetics used. Retching was counted as 1 episode
of vomiting. Case report forms were kept by the BMT nurse
practitioners and included patient age, weight, diagnosis,
prior treatment preparative regimen, daily oral intake, daily
episodes of vomiting, and PRN antiemetics used. For the
purpose of determining risk factor balance in all arms,
patients were asked to ﬁll out a questionnaire pertaining to
prior history of nausea and vomiting associated with prior
chemotherapy, radiation, or pregnancy, as well as history of
motion sickness or anticipatory nausea and vomiting.
Evaluation of Response
The following response criteria were used each day of
the antiemetic regimen. Complete response was deﬁned as
no or mild nausea (patient able to eat; reasonable intake)
and no rescue antiemetics used. Major response was deﬁned
as 1 episode of vomiting or if no vomiting occurs, moderate
nausea (intake significantly decreased, but patient can eat)
with rescue antiemetics allowed. Minor response was
deﬁned as 2 to 4 episodes of vomiting, regardless of nausea
or rescue antiemetic use. Failure was deﬁned as >4 episodes
of vomiting, regardless of nausea or rescue antiemetic use.
Major efficacy was defined as complete responders plus
major responders.
Statistical Methods
Sample size was estimated using the assumption that
patients would have a mean score of 50% ± 20%. A sample
of 34 subjects per group (n = 102) allowed for a power of
80% and a 2-sided α level of 0.025. Data analysis was con-
ducted using parametric statistical methods. Baseline bal-
ance among these groups was examined using a chi-square
test and analysis of variance for categorical and continuous
variables, respectively. The efﬁcacy score was determined as
follows. Patients were considered to have responded to the
antiemetics on a particular day if they achieved major efﬁ-
cacy as defined above (yes/no). This was determined daily
for the 4 to 8 days of antiemetic therapy. The composite
score, normalized to a maximum of 100 (ME on all days of
treatment) was determined for each patient. Differences
among the 3 groups were demonstrated using analysis of
variance. A multivariant analysis using regression techniques
was done to identify independent predictors of baseline
emesis and improvement of emesis. In all analyses, a 2-sided
P value of .05 was considered statistically signiﬁcant.
RESULTS
A total of 102 patients were randomized into the study
between September 1997 and September 1998. Six patients
withdrew from the study early (2 in each arm). One patient
in the IV arm withdrew due to an adverse drug reaction
(blurred vision on 2 occasions; attributed to dexamethasone).
(Blurred vision did not reoccur with 32 mg IV ondansetron
without dexamethasone.) The remaining 5 patients refused
to continue the protocol due to poor nausea and/or emesis
control. All patients were included in the treatment group
to which each was assigned, according to the intention-to-
treat principle.
Treatment groups were balanced with respect to age,
sex, weight, preparative regimen, and history of nausea and
vomiting with prior chemotherapy (Table 2). Days of treat-
ment ranged from 4 to 8 days.
Efficacy
Complete and major response rates for each day of the
study are shown in the Figure. Complete response rates
normalized over 8 days (Table 3) were 48% for oral
ondansetron, 47% for oral granisetron, and 49% for IV
Table 1. Preparative regimens
Preparative Regimen Oral Ondansetron Oral Granisetron IV Ondansetron Percentage of Patients
STAMP V 11 8 15 33
TBI/VP/CY 8 10 8 26
TANC 6 6 3 15
BU/CY 2 6 3 11
BEAM 2 1 1 4
BCNU/VP/CY 1 0 1 2
ICE 1 1 0 2
Carboplatin/VP 2 0 0 2
Carboplatin/MTZ/CY 0 1 1 2
MMT 1 1 0 2
Thiotepa/CY 0 0 1 1
TBI/CY 0 0 1 1
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ondansetron. Major efficacy rates normalized over 8 days
were 82% for oral ondansetron, 84% for oral granisetron,
and 81% for IV ondansetron. None of these differences
was statistically significant. Overall, 85% of patients
required rescue antiemetics on at least 1 day of their
antiemetic regimen: 91% in the oral ondansetron arm, 85%
in the oral granisetron arm, and 79% in the IV ondansetron
arm (P = .39). If an oral 5-HT3 dose was vomited within
30 minutes, requiring a repeat dose, this cost was factored
into the rescue medication cost. Most patients tolerated the
oral 5-HT3 capsules, with only 8 of 681 scheduled doses of
oral ondansetron (1%) and 3 of 472 oral granisetron (0.6%)
doses vomited within 30 minutes.
In an attempt to examine factors other than 5-HT3
antagonist treatment that may predict a patient’s composite
score, scores were compared between categories of baseline
variables. Baseline variables considered were sex; age; weight;
prior treatment (translated into a numerical value using Hes-
keth’s emetogenicity algorithm [34]); history of anticipatory
nausea and vomiting; history of nausea and vomiting (rated
by patients as mild, moderate, or severe) in response to radi-
ation, chemotherapy, or pregnancy; history of motion sick-
ness; and speciﬁc preparative regimen. Of these factors, only
history and severity of nausea (P < .01) and vomiting (P <
.02) with previous chemotherapy and/or radiation were iden-
tified as being significantly associated with the composite
score for major efﬁcacy. As may be predicted, patients who
had previously experienced nausea and vomiting with treat-
ment had lower composite scores for major efﬁcacy.
A separate subjective analysis of nausea using a 100-mm
VAS was performed. As before, results were normalized over
the treatment course. With 0 = no nausea and 100 = severe
nausea, the results were oral ondansetron 32, oral granisetron
32, and IV ondansetron 27. The differences were not statisti-
cally significant. Compliance with filling out the VAS was
less than 100%. Overall, 81% of patients ﬁlled out a VAS
form on every day of the study. Early discharge from the
hospital without the VAS forms was the most common rea-
son for noncompliance. Compliance was poorest on the IV
ondansetron arm (74% versus 82% on the oral ondansetron
arm and 88% on the oral granisetron arm). Failure to ﬁll out
the VAS forms on the last days of the study when patients
generally felt the sickest may have skewed the numbers in
favor of IV ondansetron. On the other hand, the trend in
favor of less nausea in the IV arm does follow the trend of
fewer patients requiring rescue antiemetics in this arm. The
IV ondansetron arm also had a higher percentage of patients
treated as inpatients. The inpatient setting has been reported
to have a lower incidence of chemotherapy-induced nausea
and vomiting compared to the traditional outpatient setting
[35]. This factor could theoretically also skew the results in
favor of the IV ondansetron arm. A visual inspection of inpa-
tient compared to outpatient results for identical preparative
regimens did not suggest an advantage for inpatients versus
outpatients (who spent approximately 12 hours per day in
the “day hospital”).
Cost Analysis
The cost of scheduled 5-HT3 antagonists (normalized)
was $539 for the oral ondansetron group, $684 for the oral
granisetron group, and $1651 for the IV ondansetron group.
The cost of rescue medications (normalized) using AWPs
was $102 for the oral ondansetron group, $86 for the oral
granisetron group, and $96 for the IV ondansetron group.
The oral ondansetron group had the highest rescue
antiemetic charges, but the difference was not statistically
significant (P = .23). Total costs (scheduled plus rescue
antiemetics) were $641 for the oral ondansetron, $770 for
the oral granisetron, and $1747 for the IV ondansetron arms
(P = .0001, all comparisons) (Table 4).
DISCUSSION
Most antiemetic studies published in the BMT popula-
tion have studied either IV continuous infusion serotonin
antagonists and/or higher dosages than approved by the
Table 2. Patient Demographics*
Oral Ondansetron Oral Granisetron Intravenous Ondansetron Total
Conditioning regimens
TBI-containing 8 (24) 10 (29) 9 (26) 27 (26)
Chemo only 26 (76) 24 (71) 25 (74) 75 (74)
Sex
Male 11 (32) 10 (29) 8 (24) 29 (28)
Female 23 (68) 24 (71) 26 (76) 73 (72)
Mean age, years 45 46 49 47
Mean weight, kg 80 78 76 78
Type of transplant
Allogeneic 0 1 (3) 2 (6) 3 ( 3)
Autologous 34 (100) 33 (97) 32 (94) 99 (97)
Treatment setting
Inpatient 23 (68) 23 (68) 28 (82) 74 (73)
Outpatient 11 (32) 11 (32) 6 (18) 28 (27)
History of moderate/severe nausea 22 (65) 25 (74) 26 (76) 73 (72)
History of vomiting 19 (56) 18 (53) 21 (62) 58 (57)
History of anticipatory nausea/vomiting 6 (18) 2 (6) 4 (12) 12 (12)
*Data are number of patients (%).
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U.S. Food and Drug Administration (FDA) [10,11,36-39].
Only 1 noncomparative trial has studied oral granisetron in
this setting [12]. Our study used standard FDA-approved
doses of (oral and IV) ondansetron and (oral) granisetron in
combination with IV dexamethasone. We compared our
BMT standard ondansetron dose, 32 mg IV, to an oral
ondansetron dose of 24 mg per day (8 mg every 8 hours),
which we felt to be a good comparative dose to 2 mg per day
(1 mg every 12 hours) granisetron. This assumption was
based on an approximate 10:1 equieffective dose of these
2 agents in earlier animal studies [40]. Our data showed
oral ondansetron to be equally efficacious to both oral
granisetron and 32 mg IV bolus ondansetron. Total costs of
antiemetic coverage including PRN rescue medications
were signiﬁcantly less in the oral ondansetron arm than in
either the oral granisetron or the IV ondansetron arms,
leading us to choose oral ondansetron plus dexamethasone
as the standard of care for our program. The estimated
yearly cost savings for a program that performs transplanta-
tions on 100 patients per year, assuming an average of 7 days
of oral ondansetron, is $97,000 versus IV ondansetron.
Patients did relatively well for the first 3 days of this
study regardless of the antiemetic regimen or preparative reg-
imen employed. Response rates continued to decline through-
out the 4 to 8 days of treatment, as depicted in Table 3. Most
patients required rescue antiemetics by day 4. This decline
over time mirrors that seen in other BMT studies [36,41]
and likely reﬂects the contribution of nonserotonergic neu-
rotransmitters involved in delayed nausea and vomiting [42].
Other factors, such as antibiotic and opioid use, could also
have contributed to the loss of efﬁcacy over time.
Overall, no preparative regimen showed a statistically
significant difference in response; however, the 2 most
common preparative regimens showed different trends.
Antiemetic response by day for the 3 arms. OND indicates ondansetron; GRA, granisetron; MR, major response; CR, complete response.
Table 3. Overall Response*
Oral Ondansetron Oral Granisetron IV Ondansetron
Complete response composite score, % 48 47 49
Major efficacy composite score, % 82 84 81
Failure composite score, % 4.0 3.3 2.6
VAS, mean† 32 32 27
*P = NS.
†0 = no nausea; 100 = extreme nausea.
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The most common regimen employed was STAMP V
(33% of patients). For this regimen, there was a slight
trend in favor of the 2 oral 5-HT3 arms, with more vomit-
ing seen with the IV arm. An opposite modest trend was
seen in favor of the IV arm on the day of cyclophos-
phamide 100 mg/kg in the TBI/VP/CY regimen. The
STAMP V regimen used continuous infusion chemo-
therapy, whereas high-dose cyclophosphamide was given
over 2 hours with the TBI/VP/CY regimen. No other reg-
imens showed any trends in favor of any arm.
As previously stated, only 1 other study (phase II) has
been published using an oral serotonin antagonist in the
BMT population [12]. The preparative regimens used in
this study were cyclophosphamide 6 g/m2, carboplatin
1200 mg/m2, and either etoposide 1800 mg/m2 or thiotepa
500 mg/m2, all given CIV over 96 hours. The antiemetic
regimen was oral granisetron 2 mg once daily along with
dexamethasone 4 mg PO every 6 hours and prochlorper-
azine 10 mg PO every 6 hours. A single dose of oral
lorazepam or diphenhydramine was allowed, if patients
were unable to tolerate a dose of study medication, but this
was not factored into the results. Overall, this study
showed less vomiting (53% complete response overall,
44% female patients only) and less nausea than we saw in
our study. The difference might be attributed to the inclu-
sion of prochlorperazine.
Two trials done in the BMT setting have compared CIV
ondansetron to IV granisetron. Kalaycio et al. compared IV
8 mg bolus followed by 24 mg per day CIV ondansetron to
IV 0.5 mg bolus followed by 1 mg per day CIV granisetron
in 45 patients receiving STAMP V as the preparative regi-
men [10]. All patients also received 10 mg IV bolus dexam-
ethasone. This study reported an average of 7 and 5.6 emetic
episodes per day in the IV ondansetron and granisetron
arms, respectively (not statistically signiﬁcant). In our study,
patients receiving STAMP V had an average of 0.6 emetic
episodes per day for both oral ondansetron and oral
granisetron and 1 emetic episode per day for IV bolus
ondansetron. Comparing results would suggest an inferior
response to CIV versus either oral or IV bolus 5-HT3
administration. A second study by Orchard et al. compared
CIV ondansetron to BID IV bolus granisetron in children
and adults [11]. Doses were based on weight, but were
approximately 24 mg per day ondansetron and 1 mg BID
granisetron in adults. Children received higher per-kilogram
doses than did adults. All patients also received dexametha-
sone. Complete control rates were higher in this study (61%
to 63%) than in our study (47% to 49%). The difference
may reﬂect the predominance of TBI-containing regimens
in this study (80%) compared to our trial (26%). The study
by Orchard et al. did ﬁnd that patients receiving non–TBI-
containing preparative regimens experienced significantly
more emesis (P = .04) [11].
The results of our study have demonstrated that stan-
dard doses of oral ondansetron and granisetron are similar
to single IV bolus ondansetron when combined with IV
dexamethasone. All arms effectively prevented acute nausea
and vomiting, but none were particularly effective at pre-
venting delayed nausea and vomiting. Adding a dopamine
antagonist may have improved our results [43]. Prospective
trials are needed to determine whether higher doses of
ondansetron and/or the addition of a dopamine antagonist
would decrease the incidence of delayed nausea and vomit-
ing in the BMT setting. Trials with neurokinin1 (NK1)
antagonists, the newest class of antiemetics currently being
investigated to prevent both acute and delayed nausea and
vomiting, are also warranted [44]. The ﬁrst trial of an NK1
antagonist (L-754,030) in humans has been recently pub-
lished [45]. This study showed statistically significant
improvements in both acute and delayed nausea and vomit-
ing when the NK1 antagonist was combined with granisetron
and dexamethasone versus granisetron plus dexamethasone
alone. Trials using this new class of antiemetic are anxiously
awaited in the BMT setting.
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